These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

584 related articles for article (PubMed ID: 25240272)

  • 1. Incidence of second malignancies in prostate cancer patients treated with low-dose-rate brachytherapy and radical prostatectomy.
    Hamilton SN; Tyldesley S; Hamm J; Jiang WN; Keyes M; Pickles T; Lapointe V; Kahnamelli A; McKenzie M; Miller S; Morris WJ
    Int J Radiat Oncol Biol Phys; 2014 Nov; 90(4):934-41. PubMed ID: 25240272
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Secondary cancers after intensity-modulated radiotherapy, brachytherapy and radical prostatectomy for the treatment of prostate cancer: incidence and cause-specific survival outcomes according to the initial treatment intervention.
    Zelefsky MJ; Pei X; Teslova T; Kuk D; Magsanoc JM; Kollmeier M; Cox B; Zhang Z
    BJU Int; 2012 Dec; 110(11):1696-701. PubMed ID: 22889401
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radiation therapy for prostate cancer increases subsequent risk of bladder and rectal cancer: a population based cohort study.
    Nieder AM; Porter MP; Soloway MS
    J Urol; 2008 Nov; 180(5):2005-9; discussion 2009-10. PubMed ID: 18801517
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-Term Second Malignancies in Prostate Cancer Patients Treated With Low-Dose-Rate Brachytherapy and Radical Prostatectomy.
    St-Laurent MP; Acland G; Hamilton SN; Hamm J; Sunderland K; Black PC; McKenzie M; Keyes M; Miller S; Gleave ME; Tyldesley S
    J Urol; 2024 Jul; 212(1):63-73. PubMed ID: 38603578
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The risk of second malignancies after
    Fernandez Ots A; Browne L; Chin YS; Malouf D; Wong K; Bucci J
    Brachytherapy; 2016; 15(6):752-759. PubMed ID: 27475483
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Second malignancies after prostate brachytherapy: incidence of bladder and colorectal cancers in patients with 15 years of potential follow-up.
    Liauw SL; Sylvester JE; Morris CG; Blasko JC; Grimm PD
    Int J Radiat Oncol Biol Phys; 2006 Nov; 66(3):669-73. PubMed ID: 16887293
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of age at the time of radiotherapy for localized prostate cancer on the development of second primary malignancies.
    Krasnow RE; Rodríguez D; Nagle RT; Mossanen M; Kibel AS; Chang SL
    Urol Oncol; 2018 Nov; 36(11):500.e11-500.e19. PubMed ID: 30249519
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The rate of secondary malignancies after radical prostatectomy versus external beam radiation therapy for localized prostate cancer: a population-based study on 17,845 patients.
    Bhojani N; Capitanio U; Suardi N; Jeldres C; Isbarn H; Shariat SF; Graefen M; Arjane P; Duclos A; Lattouf JB; Saad F; Valiquette L; Montorsi F; Perrotte P; Karakiewicz PI
    Int J Radiat Oncol Biol Phys; 2010 Feb; 76(2):342-8. PubMed ID: 20117287
    [TBL] [Abstract][Full Text] [Related]  

  • 9. External Beam Radiotherapy Increases the Risk of Bladder Cancer When Compared with Radical Prostatectomy in Patients Affected by Prostate Cancer: A Population-based Analysis.
    Moschini M; Zaffuto E; Karakiewicz PI; Andrea DD; Foerster B; Abufaraj M; Soria F; Mattei A; Montorsi F; Briganti A; Shariat SF
    Eur Urol; 2019 Feb; 75(2):319-328. PubMed ID: 30293908
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Commentary on "secondary cancers after intensity-modulated radiotherapy, brachytherapy, and radical prostatectomy for the treatment of prostate cancer: incidence and cause-specific survival outcomes according to the initial treatment intervention." Zelefsky MJ, Pei X, Teslova T, Kuk D, Magsanoc JM, Kollmeier M, Cox B, Zhang Z. Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY.: BJU Int 2012;110:1696-701. doi: 10.1111/j.1464-410X.2012.11385.x. [Epub 2012 Aug 13].
    Gottschalk A
    Urol Oncol; 2014 Feb; 32(2):209. PubMed ID: 24445290
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Permanent 125I-seed brachytherapy or radical prostatectomy: a prospective comparison considering oncological and quality of life results.
    Borchers H; Kirschner-Hermanns R; Brehmer B; Tietze L; Reineke T; Pinkawa M; Eble MJ; Jakse G
    BJU Int; 2004 Oct; 94(6):805-11. PubMed ID: 15476513
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostate brachytherapy and second primary cancer risk: a competitive risk analysis.
    Hinnen KA; Schaapveld M; van Vulpen M; Battermann JJ; van der Poel H; van Oort IM; van Roermund JG; Monninkhof EM
    J Clin Oncol; 2011 Dec; 29(34):4510-5. PubMed ID: 22025166
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Second primary cancers occurring after I-125 brachytherapy as monotherapy for early prostate cancer.
    Musunuru H; Mason M; Murray L; Al-Qaisieh B; Bownes P; Smith J; Franks K; Carey B; Bottomley D; Henry AM
    Clin Oncol (R Coll Radiol); 2014 Apr; 26(4):210-5. PubMed ID: 24507938
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Brachytherapy improves biochemical failure-free survival in low- and intermediate-risk prostate cancer compared with conventionally fractionated external beam radiation therapy: a propensity score matched analysis.
    Smith GD; Pickles T; Crook J; Martin AG; Vigneault E; Cury FL; Morris J; Catton C; Lukka H; Warner A; Yang Y; Rodrigues G
    Int J Radiat Oncol Biol Phys; 2015 Mar; 91(3):505-16. PubMed ID: 25596107
    [TBL] [Abstract][Full Text] [Related]  

  • 15. External Beam Radiation Therapy With a Brachytherapy Boost Versus Radical Prostatectomy in Gleason Pattern 5 Prostate Cancer: A Population-Based Cohort Study.
    Wang C; Kishan AU; Kamrava M; Steinberg ML; King CR
    Int J Radiat Oncol Biol Phys; 2017 Aug; 98(5):1045-1052. PubMed ID: 28721887
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radical prostatectomy versus high-dose rate brachytherapy for prostate cancer: effects on health-related quality of life.
    Jo Y; Junichi H; Tomohiro F; Yoshinari I; Masato F
    BJU Int; 2005 Jul; 96(1):43-7. PubMed ID: 15963118
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk for developing myelodysplastic syndromes in prostate cancer patients definitively treated with radiation.
    Mukherjee S; Reddy CA; Ciezki JP; Abdel-Wahab M; Tiu RV; Copelan E; Advani AA; Saunthararajah Y; Paulic K; Hobson S; Maciejewski JP; Bolwell BJ; Kalaycio M; Dreicer R; Klein EA; Sekeres MA
    J Natl Cancer Inst; 2014 Mar; 106(3):djt462. PubMed ID: 24577815
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radical prostatectomy vs radiation therapy and androgen-suppression therapy in high-risk prostate cancer.
    Westover K; Chen MH; Moul J; Robertson C; Polascik T; Dosoretz D; Katin M; Salenius S; D'Amico AV
    BJU Int; 2012 Oct; 110(8):1116-21. PubMed ID: 22540922
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Direct comparison of low-dose-rate brachytherapy versus radical prostatectomy using the surgical definition of biochemical recurrence for patients with intermediate-risk prostate cancer.
    Tsumura H; Tanaka N; Oguchi T; Owari T; Nakai Y; Asakawa I; Iijima K; Kato H; Hashida I; Tabata KI; Satoh T; Ishiyama H
    Radiat Oncol; 2022 Apr; 17(1):71. PubMed ID: 35410307
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Second malignancies after adjuvant radiation therapy for early stage breast cancer: is there increased risk with addition of regional radiation to local radiation?
    Hamilton SN; Tyldesley S; Li D; Olson R; McBride M
    Int J Radiat Oncol Biol Phys; 2015 Apr; 91(5):977-85. PubMed ID: 25832690
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.